Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
Year: 2022
Type: article
Source: Blood
Authors: Philippe Moreau, Thierry Facon, Saad Usmani, Nizar Jacques Bahlis, Noopur Raje, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Shaji K Kumar
Institutions: Université de Lille, Centre Hospitalier Universitaire de Lille, Memorial Sloan Kettering Cancer Center, University of Calgary, Massachusetts General Hospital, University of Southern Denmark, Vejle Sygehus, The University of Texas MD Anderson Cancer Center, University of Wolverhampton, The Royal Wolverhampton NHS Trust, Karolinska University Hospital, Karolinska Institutet, Hôpital Cardiologique du Haut-Lévêque, St Vincent's Hospital Melbourne, Heidelberg University, University Hospital Heidelberg, National Center for Tumor Diseases, Ollscoil na Gaillimhe – University of Galway, Université Toulouse III - Paul Sabatier, Institut universitaire du cancer de Toulouse Oncopole, Université de Toulouse, University of Alberta, Cross Cancer Institute, University Medical Center Hamburg-Eppendorf, Centre Hospitalier Départemental Vendée, Centre Hospitalier Universitaire de Caen Normandie, Hôpital Necker-Enfants Malades, Centre Hospitalier Universitaire de Poitiers, Janssen Research & Development (United States), Mayo Clinic
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310099098